These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 11181127)
1. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. El-Sadr WM; Perlman DC; Denning E; Matts JP; Cohn DL Clin Infect Dis; 2001 Feb; 32(4):623-32. PubMed ID: 11181127 [TBL] [Abstract][Full Text] [Related]
2. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100 [TBL] [Abstract][Full Text] [Related]
3. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000. Li J; Munsiff SS; Driver CR; Sackoff J Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767 [TBL] [Abstract][Full Text] [Related]
4. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Jones BE; Otaya M; Antoniskis D; Sian S; Wang F; Mercado A; Davidson PT; Barnes PF Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1499-502. PubMed ID: 7952606 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration. Johnson JL; Okwera A; Nsubuga P; Nakibali JG; Whalen CC; Hom D; Cave MD; Yang ZH; Mugerwa RD; Ellner JJ Int J Tuberc Lung Dis; 2000 Nov; 4(11):1032-40. PubMed ID: 11092715 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813 [TBL] [Abstract][Full Text] [Related]
7. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Chaisson RE; Clermont HC; Holt EA; Cantave M; Johnson MP; Atkinson J; Davis H; Boulos R; Quinn TC; Halsey NA Am J Respir Crit Care Med; 1996 Oct; 154(4 Pt 1):1034-8. PubMed ID: 8887603 [TBL] [Abstract][Full Text] [Related]
8. FDA approves rifapentine for the treatment of pulmonary tuberculosis.... Food and Drug Administration. Roehr B J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):19-25. PubMed ID: 11365728 [TBL] [Abstract][Full Text] [Related]
9. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Schluger NW Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083 [TBL] [Abstract][Full Text] [Related]
10. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda. Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516 [TBL] [Abstract][Full Text] [Related]
11. Nutritional status of persons with HIV infection, persons with HIV infection and tuberculosis, and HIV-negative individuals from southern India. Swaminathan S; Padmapriyadarsini C; Sukumar B; Iliayas S; Kumar SR; Triveni C; Gomathy P; Thomas B; Mathew M; Narayanan PR Clin Infect Dis; 2008 Mar; 46(6):946-9. PubMed ID: 18279043 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months. Perriëns JH; St Louis ME; Mukadi YB; Brown C; Prignot J; Pouthier F; Portaels F; Willame JC; Mandala JK; Kaboto M N Engl J Med; 1995 Mar; 332(12):779-84. PubMed ID: 7862181 [TBL] [Abstract][Full Text] [Related]
14. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Korenromp EL; Scano F; Williams BG; Dye C; Nunn P Clin Infect Dis; 2003 Jul; 37(1):101-12. PubMed ID: 12830415 [TBL] [Abstract][Full Text] [Related]
15. Tuberculosis and HIV infection: epidemiology, immunology, and treatment. Schluger NW; Burzynski J HIV Clin Trials; 2001; 2(4):356-65. PubMed ID: 11590540 [TBL] [Abstract][Full Text] [Related]
16. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults. Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099 [TBL] [Abstract][Full Text] [Related]
17. Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa. Harries AD; Hargreaves NJ; Salaniponi FM Int J Tuberc Lung Dis; 2001 Dec; 5(12):1109-15. PubMed ID: 11769768 [TBL] [Abstract][Full Text] [Related]
18. [Efficacy of a short 6 month therapeutic coursefor HIV infected tuberculosis patients in Abidjan, Côte d'Ivoire]. Domoua K; N'Dhatz M; Coulibaly G; Traore F; Koffi J; Achi V; Daix T; Ouattara Y; Ouedraogo M; Beugre LK; Konan JB; Coulibaly V; Coulibaly IM; Yapi A Bull Soc Pathol Exot; 1998; 91(4):312-4. PubMed ID: 9846224 [TBL] [Abstract][Full Text] [Related]